Skip to NavigationSkip to content

Novartis forge deal with Boston Pharmaceuticals in effort against AMR

Published on 03/10/18 at 11:15am

Swiss multinational Novartis have entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug candidates in an effort to boost Novartis’ Infectious Diseases portfolio. It is hoped that the deal may help tackle antibiotic resistant infections in the future.

“The need for new antibiotics that address drug resistant bacteria is clear and we are pleased to find a partner in Boston Pharmaceuticals who will dedicate the appropriate expertise and resources for the further development and commercialization of these programs,” said Dr Jay Bradner, President of the Novartis Institutes for BioMedical Research.

“Drug discovery and development is a team sport and this agreement is part of our strategy to partner with like -minded innovators outside of our walls to further develop new innovative medicines focused on addressing global health challenges.”

Under the terms of the agreement Novartis will receive an upfront payment while also being entitled to royalties. Novartis will also gain an equity share in the Cambridge, Massachusetts-based pharma firm.

“The acquisition of these three novel anti-infective candidates further demonstrates our commitment to addressing unmet medical needs in order to benefit patients,” said Robert Armstrong, Ph.D., C.E.O. of Boston Pharmaceuticals.

“Novartis has done a tremendous job advancing new solutions to infections caused by drug resistant Gram-negative pathogens and developing these innovative candidates with best-in-class or first-in-class potential. We look forward to building on this quality research as we advance these candidates.”

Louis Goss

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches